16 results
The objective of the proposed research is to address the effectiveness of neurofeedback and exercise as non-pharmacological treatments for ADHD. The effects of neurofeedback and exercise will be assessed on three domains: behaviour, neurocognition,…
To investigate whether impairments of shifting between response sets underlie motor freezing in PD and to investigate the efficacy and the neural mechanism by which MPH improves gait and cognition in PD patients with FOG.
To explore the efficacy and safety of an oral IP receptor agonist in an inoperable or persistent/recurrent CTEPH population treated with standard of care.
-The primary objective of this study is to investigate the pharmacokinetics (PK) of olaparib after a single oral dose of 300 mg to patients with advanced solid tumours and mild or moderate hepatic impairment compared to those with normal hepatic…
PrimaryTo assess the safety and tolerability of olaparib when given in addition to abiraterone and torecommend, by assessment of dose-limiting toxicities and other safety and tolerability data, adose of olaparib for further study when given in…
The primary objective of this study is to investigate the effect of food on the pharmacokinetics (PK) of olaparib following oral dosing of the capsule formulation in patients with advanced solid tumours.The secondary objective is to further…
The primary objective of this study is to investigate the effect of itraconazole on thepharmacokinetics (PK) of olaparib following oral dosing of the tablet formulation inpatients with advanced solid tumours.The secondary objectives are: to…
The primary objective of this study is to investigate the effect of food on the pharmacokinetics(PK) of olaparib following oral dosing of the tablet formulation in patients with advancedsolid tumours.The secondary objectives are to investigate the…
-The primary objective of this study is to investigate the pharmacokinetics of olaparib after a single oral dose of 300 mg to patients with advanced solid tumours and mild or moderate renal impairment compared to those with normal renal function.-…
* The primary objective of this study is to investigate the effect of rifampicin on the pharmacokinetics (PK) of olaparib following oral dosing of the tablet formulation in patients with advanced solid tumours.* The secondary objectives are to…
To determine whether addition of selexipag to current PAH therapy improves exercise capacity, imaging parameters and quality of life, delays time-to-first-PAH-related morbidity and mortality, prevents worsening of World Health Organization…
Main objective:To assess the effects of selexipag on right ventricular (RV) function in participants with PAH.Secondary objectives:- To further assess the effects of selexipag on RV function using MRI.- To assess the effects of selexipag on disease…
The primary objective of this study is to determine the immune-activating capacity of treatment with pembrolizumab and carboplatin/paclitaxel in the neo-adjuvant setting of primary stage IV ovarian cancer as measured by the alteration in magnitude…
Primary:To compare the efficacy of olaparib when given in addition to abiraterone, with placebo givenin addition to abiraterone, by assessment of radiologic progression-free survival (rPFS) usingResponse Evaluation Criteria in Solid Tumours version…
The aim of the present study is to investigate whether selexipag could be helpful to treat patients with another form of PH called sarcoidosis-associated pulmonary hypertension (SAPH).
To assess the effect of MEDI4736 in combination with olaparib±bevacizumab in patients with selected advanced solid tumors.To assess the safety and tolerability of MEDI4736 in combination with olaparib (±bevacizumab) in patients with selected…